Barclays analyst Peter Lawson lowered the firm’s price target on Syndax to $32 from $34 and keeps an Overweight rating on the shares. The analyst de-risked the model post the company’s Q3 report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SNDX:
- Syndax reports Q3 EPS (73c), consensus (78c)
- Syndax Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update
- Oppenheimer biotechnology analyst to hold an analyst/industry conference call
- Syndax’s axatilimab shows safety and efficacy in graft-versus-host disease
- Bank of America Says Contrarian Buy Signal Could Push Stocks Higher; Here Are 2 Names the Banking Giant Likes Right Now